Navigation Links
Goodwin Biotechnology and Coldstream Laboratories Announce a Collaboration to Develop and Manufacture Cytotoxic Antibody Drug Conjugates
Date:4/25/2013

PLANTATION, Fla. and LEXINGTON, Ky., April 25, 2013 /PRNewswire/ -- Goodwin Biotechnology, Inc. (GBI) and Coldstream Laboratories, Inc. have established a collaboration for developing and manufacturing high-potency, highly cytotoxic materials (e.g., small molecules, protein toxins, cytotoxic antibody drug conjugates, and other bioconjugates).

"Over the last 20 years, GBI has offered cell culture and purification process development, scale-up, GLP manufacturing and cGMP manufacturing services for cell culture-derived biopharmaceuticals as a contract manufacturing organization (CMO)," noted Muctarr Sesay , PhD, Vice President of Process Development at GBI. "For more than a decade, we have augmented these services by leveraging the bioconjugation experience and expertise of our staff to develop Antibody Drug Conjugates (ADCs), radioimmunoconjugates and other bioconjugates. To address growing market demands for ADCs employing highly potent and cytotoxic therapeutic payloads, it has recently become clear that a collaboration is needed with a company that has high-containment and isolation capabilities relative to the handling, processing, characterization, fill and finish, lyophilization, and storage of these cytotoxic materials.  The resultant products are designed to provide highly specific targeting of cancer cells, for example, and enhanced cell killing ability. The result will be improved therapeutic effectiveness with minimal toxicity when compared to traditional therapeutic approaches."

"Coldstream is also a CMO, tracing its origins to the University of Kentucky's Center for Pharmaceutical Sciences and Technology, and we offer small-volume, parenteral manufacturing services," said Eric W. Smart , President & CEO of Coldstream Laborato
'/>"/>

SOURCE Goodwin Biotechnology, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lixte Biotechnology Announces Initiation Of A Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100
2. Cytos Biotechnology Ltd Reports First Quarter 2013 Financial Results and Recent Development
3. Plandai Biotechnology, Inc. Announces Shipment Of First Machinery To South African Production Facility
4. PharmaLeaders: Innovative Mid-Cap Biotechnology Benchmark Report - Financial Benchmarking, Pipeline Assessment & Competitive Analysis of Innovative Biotechs
5. Choose New Jersey and Partners to Promote New Jersey As Global Life Science Hub at Worlds Largest Biotechnology Event
6. Plandai Biotechnology, Inc. Enters Into License Agreement With Phyto Nutricare To Develop Nutraceutical Products
7. Biotechnology Market (Biopharmacy, Bioservices, Bioagri, Bioindustrial) Is Expected to Reach USD 414.5 Billion Globally in 2017: Transparency Market Research
8. NanoSight, One of the UKs Fastest Growing Biotechnology Companies, Wins a 2013 Queens Award for Enterprise - Innovation
9. Global Biotechnology Industry Market Research Report Now Available from IBISWorld
10. Plandai Biotechnology, Inc. Updates Progress Of Preparing Products For Market
11. San Diego State University Hosts Open House for Life Science Immersion Biotechnology Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- Nuvilex, Inc. (OTCQB: NVLX) – According to the ... living with diabetes, with  that number expected to grow ... for diabetes treatments is approximately $500 billion.  ... pancreatic cancer.  Pancreatic cancer is the fourth most common ... the United States , and according to a ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 The ... (Medication Dispensing Systems, Packaging and Labeling Systems, Table-top ... Automation) - Global Forecasts & Trends to 2019” ... and opportunities in North America, Europe, Asia-Pacific, and ... 101 market tables and 30 figures spread through ...
(Date:10/20/2014)... , Oct. 20, 2014 Asterias ... the Company has signed a Notice of Grant ... Medicine (CIRM), effective October 1, 2014.  The NGA ... payments and the release of additional grant funds ... grant award for clinical development of Asterias, product, ...
(Date:10/20/2014)... GAITHERSBURG, Md. , Oct. 20, 2014  GenVec, Inc. ... Zola P. Horovitz , Ph.D., from its board of ... GenVec board in August 2003, and served as its chairman ... also served on the Nominating and Corporate Governance and Audit ... Zola for more than a decade of dedicated service to ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Zola P. Horovitz To Retire From GenVec Board 2
... on nanoimprinting techniques (NIL) is evolving at a rapid pace. ... in order to reach the market? How do we bridge ... industry? What are the tools needed for each product? ... to life science products were discussed by more than 80 ...
... Inc. ("CTI" or the "Company") (NASDAQ and MTA: CTIC) today ... of 2012. First Quarter Financial ResultsFor ... $18.1 million compared to $20.1 million for the same period ... to $17.4 million ($0.09 per share) for the quarter ended ...
... Fla., April 19, 2012  New data presented today ... delivering inhaled nitric oxide (NO) to patients being ... ), a privately held, advanced development-stage technology company, ... System during Right Heart Catheterization (RHC) in subjects ...
Cached Biology Technology:Tackling the European market of nanoimprint lithography 2Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones 2Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones 3Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones 4Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones 5New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation 2New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation 3New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation 4
(Date:10/19/2014)... access in India over the last 30 years ... emissions growth during that time, according to a ... Climate Change ., "Energy access is fundamental to ... life, including education, communication, and health," says IIASA ... While increased energy access is widely agreed to ...
(Date:10/17/2014)... Rockville, MD – Accurate knowledge regarding Ebola is critical ... current risk of hazardous global outbreak and epidemic. The ... has launched a special issue, Ebola Virus and Public ... with necessary knowledge in this critical societal moment. ... Primer on Ebola for Clinicians . The primer was ...
(Date:10/16/2014)... body. Battles are won, lost or sometimes end ... as tumor dormancy—can last up to 25 years ... poorly understood. , A new computational model ... Professor of Chemistry at Princeton University, may help ... switch to a malignant state. Published today in ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Modeling tumor dormancy 2
... 2010 Imagine creating novel devices with amazing and ... a droplet of particles on a surface. By ... team of Harvard researchers, in collaboration with scientists at ... the University of Houston, has developed just that. ...
... Ardipithecus ramidus a purported human ancestor ... is coming under fire from scientists who say there ... dense woodlands at the African site where the creature lived ... for open savanna habitats," says University of Utah geochemist Thure ...
... State University College of Medicine researcher has discovered a new ... that may be the cause of B-cell lymphoma. The finding ... of other types of cancer, leading to further understanding of ... Yoichi Kato, an assistant professor in the Department ...
Cached Biology News:Applied physicists create building blocks for a new class of optical circuits 2Applied physicists create building blocks for a new class of optical circuits 3Out of the woods for 'Ardi' 2Out of the woods for 'Ardi' 3Out of the woods for 'Ardi' 4Medical researcher's discovery may explain how certain cancers develop 2
... 97 Cytological Labeling Kit provides a unique ... of cellular targets, including cell-surface receptors and ... Kit contains the patented ELF 97 phosphatase ... precipitate at the site of enzymatic activity ...
... between the various commercial and lab-prepared glass ... the length and GC content of the ... protocol employed all influence the optimal hybridization ... all the different variables to consider, it ...
... Stain combo offers these benefits: ... Offers a safer and ... Eliminates risks to yourself, the environment and your ... bp to >30 kb. UltraPure Agarose is a standard ...
This is a PYREX replacement Allihn condenser with a 34/45 inner joint on the bottom for the No. CLS3840-S 125mL extractor system. The tubulation O.D. on the condenser is 10mm....
Biology Products: